Price
$3.41
Increased by +1.79%
Dollar Volume
1.37 M
ADR%
10.55
Market Cap.
315.07 M
Shares Float
42.22 M
Shares Outstanding
92.39 M
Beta
0.00
Price / Earnings
-1.92
BPR
19.79
20D Range
2.28 3.63
50D Range
1.94 3.63
200D Range
1.94 8.06
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 22 -0.30
Increased by +9.09%
-0.28
Decreased by -7.14%
Aug 11, 22 -0.32
Increased by +86.61%
-0.30
Decreased by -6.67%
May 11, 22 -0.33 -0.29
Decreased by -13.79%
Mar 22, 22 -0.28 -0.25
Decreased by -12.00%
Nov 9, 21 -0.33 -0.18
Decreased by -83.33%
Sep 7, 21 -2.39 -0.85
Decreased by -181.18%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 2.37 M
Increased by +53.93%
-27.26 M
Decreased by -15.34%
Decreased by -1.15 K%
Increased by +25.07%
Jun 30, 22 1.00 M
Increased by +37.64%
-28.68 M
Increased by +30.38%
Decreased by -2.86 K%
Increased by +49.42%
Mar 31, 22 819.00 K
Decreased by -22.95%
-29.49 M
Decreased by -169.06%
Decreased by -3.60 K%
Decreased by -249.22%
Dec 31, 21 -815.00 K
Decreased by -129.88%
-25.17 M
Decreased by -409.54%
Increased by +3.09 K%
Increased by +1.81 K%
Sep 30, 21 1.54 M
Increased by +68.01%
-23.63 M
Decreased by -530.58%
Decreased by -1.54 K%
Decreased by -275.31%
Jun 30, 21 728.00 K
Increased by +29.08%
-41.20 M
Decreased by -1.27 K%
Decreased by -5.66 K%
Decreased by -961.07%
Mar 31, 21 1.06 M
Increased by +85.84%
-10.96 M
Decreased by -312.42%
Decreased by -1.03 K%
Decreased by -121.92%
Dec 31, 20 2.73 M - -4.94 M -
Decreased by -181.05%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.